Superamento della resistenza al cancro al seno attraverso la degradazione di proteine mirata e chimere di nuova generazione.

Proteolysis-Targeting Chimeras (PROTACs) represent a paradigm shift from occupancy-driven inhibition to event-driven protein elimination in cancer therapy. By harnessing the ubiquitin-proteasome system, PROTACs catalytically degrade disease-driving proteins. In breast cancer, the most commonly diagnosed cancer in women globally, PROTAC technology has advanced rapidly from preclinical concept to clinical validation. This review systematically evaluates PROTAC development across multiple therapeutic targets in breast cancer, including estrogen receptor α (ERα), human epidermal growth factor receptor 2 (HER2), bromodomain-containing protein 4 (BRD4), poly(ADP-ribose) polymerase 1 (PARP1), cycli